Molecular Biomarkers for the Evaluation of Colorectal Cancer
作者： Antonia R. Sepulveda , Stanley R. Hamilton , Carmen J. Allegra , Wayne Grody , Allison M. Cushman-Vokoun
DOI: 10.1016/J.JMOLDX.2016.11.001
关键词:
摘要: Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing colorectal cancer (CRC) tissues guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College Pathologists, Association Molecular Oncology convened an expert panel patients with CRC. A comprehensive search that included more than 4,000 articles was conducted. Results: Twenty-one statements were established. Conclusions: Evidence supports mutational EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors benefit anti-EGFR monoclonal antibody targeted therapy Mutations in several biomarkers have clear prognostic value. Laboratory approaches operationalize CRC are presented. Key Words: diagnostics; Gastrointestinal; Histology; Genetics; Oncology.
jmdjournal.org
elsevier.com参考文章(145)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine. ,vol. 373, pp. 1979- 1979 ,(2015) , 10.1056/NEJMC1510353
Medical Advisory Secretariat, KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. Ontario health technology assessment series. ,vol. 10, pp. 1- 49 ,(2010)
Oscar Nappi, Vincenzo Iaffaioli, Gerardo Botti, Nicola Normanno, Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, Fabiana Tatangelo, Carmine Pinto, Fortunato Ciardiello, Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics. ,vol. 11, pp. 1169- 1179 ,(2010) , 10.2217/PGS.10.86
Tolia M, Tsoukalas N, Kostakis Id, Ardavanis A, Tzovaras Aa, Papakostidi A, Pistamaltzian N, Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. ,vol. 17, pp. 73- ,(2012)
Jennifer S Lin, Elizabeth M Webber, Caitlyn A Senger, Rebecca S Holmes, Evelyn P Whitlock, Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer American Journal of Cancer Research. ,vol. 1, pp. 650- 662 ,(2011)
William K. Funkhouser, Ira M. Lubin, Federico A. Monzon, Barbara A. Zehnbauer, James P. Evans, Shuji Ogino, Jan A. Nowak, Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. The Journal of Molecular Diagnostics. ,vol. 14, pp. 91- 103 ,(2012) , 10.1016/J.JMOLDX.2011.11.001
Michelle Mancher, Dianne Miller Wolman, Sheldon Greenfield, Robin Graham, Earl Steinberg, Clinical Practice Guidelines We Can Trust ,(2013)
Wilbur A. Franklin, Jerry Haney, Michio Sugita, Lynne Bemis, Antonio Jimeno, Wells A. Messersmith, KRAS Mutation The Journal of Molecular Diagnostics. ,vol. 12, pp. 43- 50 ,(2010) , 10.2353/JMOLDX.2010.080131
S.A. Forbes, G. Bhamra, S. Bamford, E. Dawson, C. Kok, J. Clements, A. Menzies, J.W. Teague, P.A. Futreal, M.R. Stratton, The Catalogue of Somatic Mutations in Cancer (COSMIC). Current protocols in human genetics. ,vol. 57, ,(2008) , 10.1002/0471142905.HG1011S57
Zu‐Yao Yang, Xin‐Yin Wu, Ya‐Fang Huang, Meng‐Yang Di, Da‐Yong Zheng, Jin‐Zhang Chen, Hong Ding, Chen Mao, Jin‐Ling Tang, None, Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. International Journal of Cancer. ,vol. 133, pp. 1914- 1925 ,(2013) , 10.1002/IJC.28153